Cyclerion Therapeutics Inc (CYCN)

Cyclerion to combine with Korsana Biosciences in $380 million merger deal

April 1, 2026

Cyclerion Therapeutics (NASDAQ:CYCN) announced it has signed a definitive merger agreement with privately held Korsana Biosciences in an all-stock transaction, according to a company press release. The announcement comes as Cyclerion shares trade around $1.55, giving the company a market capitalization of roughly $5.9 million, with the stock down 4.3% over the past week.

Following the transaction, the merged business will operate under the name Korsana Biosciences and will trade on Nasdaq under the ticker KRSA. Current Cyclerion shareholders are expected to hold about 1.5% of the combined company, while existing Korsana investors will control approximately 98.5%.

Korsana has also secured investor commitments for a private financing expected to generate approximately $380 million in gross proceeds, led by Fairmount and Venrock Healthcare Capital Partners. The financing will include common shares and pre-funded warrants exercisable for Korsana stock and is expected to close immediately before the merger is finalized.

The companies expect that the combined entity’s cash position at closing will support operations through 2029. Korsana’s lead drug candidate, KRSA-028, is a monoclonal antibody targeting amyloid beta being developed as a treatment for Alzheimer’s disease.

The company anticipates Phase 1 data from healthy volunteers by mid-2027, followed by interim proof-of-concept results measuring amyloid plaque reduction in Alzheimer’s patients by the end of 2027.

KRSA-028 is built on the Therapeutic Targeting platform, which incorporates transferrin receptor and Fc engineering technologies designed to enhance delivery of therapies to the brain. The treatment is being developed for subcutaneous administration.

Jonathan Violin, President and Chief Executive Officer of Korsana, will serve as CEO of the combined company. The current Korsana board of directors will also form the board of the new entity, with Tomas Kiselak of Fairmount serving as chairman.

Both companies’ boards have approved the deal, which is expected to close in the third quarter of 2026, pending shareholder approval, SEC registration effectiveness, expiration of the Hart-Scott-Rodino waiting period, and other customary conditions.

Wedbush Securities is acting as financial advisor to Korsana, while Gemini Valuation Services is serving as financial advisor to Cyclerion.

In separate developments, Cyclerion recently received positive written feedback from the U.S. Food and Drug Administration regarding its planned Phase 2 proof-of-concept study of CYC-126 for treatment-resistant depression. The agency’s feedback provided clarity on the regulatory pathway and supported key elements of the proposed study design.

Cyclerion also announced a strategic partnership with Medsteer aimed at advancing its closed-loop anesthetic platform for this indication. The agreement is exclusive and application-specific, focusing on integrating Medsteer’s proprietary technology into Cyclerion’s lead program, CYC-126.

The collaboration will incorporate EEG-guided monitoring technology, enabling more precise and individualized treatment using anesthetic agents with real-time monitoring and algorithm-based dosing. These steps mark continued progress in Cyclerion’s efforts to develop therapies for treatment-resistant depression.

Link article

$CYCN 🗞️

I hear Big Fun here!

Cyclerion to combine with Korsana Biosciences in $380 million merger dealApril 1, 2026 10:47 AM
IH Market News
Cyclerion Therapeutics (NASDAQ:CYCN) announced it has signed a definitive merger agreement with privately held Korsana Biosciences in an all-stock transaction, according to a company press release. The announcement comes as Cyclerion shares trade around $1.55, giving the company a market capitalization of roughly $5.9 million, with the stock down 4.3% over the past week.Following the transaction, the merged business will operate under the name Korsana Biosciences and will trade on Nasdaq under the ticker KRSA. Current Cyclerion shareholders are expected to hold about 1.5% of the combined company, while existing Korsana investors will control approximately 98.5%.Korsana has also secured investor commitments for a private financing expected to generate approximately $380 million in gross proceeds, led by Fairmount and Venrock Healthcare Capital Partners. The financing will include common shares and pre-funded warrants exercisable for Korsana stock and is expected to close immediately before the merger is finalized.The companies expect that the combined entity’s cash position at closing will support operations through 2029. Korsana’s lead drug candidate, KRSA-028, is a monoclonal antibody targeting amyloid beta being developed as a treatment for Alzheimer’s disease.The company anticipates Phase 1 data from healthy volunteers by mid-2027, followed by interim proof-of-concept results measuring amyloid plaque reduction in Alzheimer’s patients by the end of 2027.KRSA-028 is built on the Therapeutic Targeting platform, which incorporates transferrin receptor and Fc engineering technologies designed to enhance delivery of therapies to the brain. The treatment is being developed for subcutaneous administration.Jonathan Violin, President and Chief Executive Officer of Korsana, will serve as CEO of the combined company. The current Korsana board of directors will also form the board of the new entity, with Tomas Kiselak of Fairmount serving as chairman.Both companies’ boards have approved the deal, which is expected to close in the third quarter of 2026, pending shareholder approval, SEC registration effectiveness, expiration of the Hart-Scott-Rodino waiting period, and other customary conditions.Wedbush Securities is acting as financial advisor to Korsana, while Gemini Valuation Services is serving as financial advisor to Cyclerion.In separate developments, Cyclerion recently received positive written feedback from the U.S. Food and Drug Administration regarding its planned Phase 2 proof-of-concept study of CYC-126 for treatment-resistant depression. The agency’s feedback provided clarity on the regulatory pathway and supported key elements of the proposed study design.Cyclerion also announced a strategic partnership with Medsteer aimed at advancing its closed-loop anesthetic platform for this indication. The agreement is exclusive and application-specific, focusing on integrating Medsteer’s proprietary technology into Cyclerion’s lead program, CYC-126.The collaboration will incorporate EEG-guided monitoring technology, enabling more precise and individualized treatment using anesthetic agents with real-time monitoring and algorithm-based dosing. These steps mark continued progress in Cyclerion’s efforts to develop therapies for treatment-resistant depression.Cyclerion Therapeutics stock price

Original: Cyclerion to combine with Korsana Biosciences in $380 million merger deal

$CYCN: AMazing.......... $8.30

Just been watching it like a bum from the sidelines all morning................ shoulda stepped into it

Ughhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh


GO $CYCN

cycn.............................................p/m

Cyclerion Therapeutics and Korsana Biosciences Announce Merger AgreementApril 1, 2026 7:05 AM
Business Wire
Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases


Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease


Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027


Conference call scheduled for April 1, 2026, at 8:00 am ET


Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Korsana Biosciences, Inc. and trade on Nasdaq under the ticker symbol “KRSA.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401287952/en/
In support of the proposed merger, Korsana has secured commitments for an oversubscribed private investment that is expected to result in total gross proceeds of approximately $380 million from a syndicate of investors led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, Wellington Management, Commodore Capital, RA Capital Management, RTW Investments, Vivo Capital, Janus Henderson Investors, Foresite Capital, J.P. Morgan Life Sciences Private Capital, SR One, Sanofi Ventures, Kalehua Capital, Spruce Street Capital, and other leading investment management firms. The financing includes common stock and pre-funded warrants exercisable for shares of Korsana common stock.


The financing is expected to close immediately prior to completion of the proposed merger. The combined company’s cash and cash equivalents balance at closing, including the funds from the private placement, is anticipated to fund Korsana’s operations into 2029 and provides runway through key clinical milestones. These include the advancement of KRSA-028 through Phase 1 healthy volunteer data expected in mid-2027 and interim proof of concept data measuring amyloid plaque clearance in Alzheimer’s patients expected by the end of 2027.


“Korsana is determined to deliver breakthrough medicines for patients suffering from neurodegenerative disorders. With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies,” said Jonathan Violin, Ph.D., Korsana’s President and Chief Executive Officer. “Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s disease. We are also building a broader pipeline leveraging our proprietary platform to target other devastating neurodegenerative disorders.”


Korsana is the seventh company to launch with assets discovered and developed by Paragon Therapeutics. Korsana’s lead program is KRSA-028, a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics. KRSA-028 utilizes the proprietary Therapeutic Targeting (THETA™) platform, which incorporates clinically validated transferrin receptor (TfR1) and Fc engineering and is designed to improve brain delivery and solve limitations of other TfR1-based approaches. KRSA-028 was designed to increase amyloid plaque clearance, reduce the rate of amyloid-related imaging abnormalities (ARIA) and hematologic adverse events, and optimize convenience and compliance with a low-volume subcutaneous route of administration. Korsana is advancing a pipeline of innovative THETA-enabled therapies for other undisclosed, neurodegenerative diseases with high unmet need.


“Our transaction with Korsana is the result of a comprehensive strategic review, and we believe it represents the best path forward for Cyclerion,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “Korsana’s promising and innovative pipeline targeting neurodegenerative disorders, beginning with Alzheimer’s disease, provides the potential for significant value creation for Cyclerion’s shareholders.”


About the Proposed Transactions


Under the terms of the merger agreement, as of the closing of the proposed merger, the pre-merger Cyclerion shareholders are expected to own approximately 1.5% of the combined company and the pre-merger Korsana stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own approximately 98.5% of the combined company. The percentage of the combined company that Cyclerion’s shareholders will own as of the closing of the proposed merger is subject to adjustment based on the estimated amount of Cyclerion’s net cash immediately prior to the closing date.


The transaction has received approval by the Board of Directors of both companies and is expected to close in the third quarter of 2026, subject to certain closing conditions, including, among others, approval by the stockholders of each company, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (the “SEC”) to register the securities to be issued in connection with the proposed merger, expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the satisfaction of other customary closing conditions.


The combined company plans to operate under the name Korsana Biosciences, Inc. and will be led by Dr. Violin, Korsana’s current Chief Executive Officer. Korsana’s existing Board of Directors will become directors of the combined company, chaired by Tomas Kiselak, Founding Partner at Fairmount, and including Andrew Gottesdiener, M.D., Partner at Venrock Healthcare Capital Partners, Nilesh Kumar, Ph.D., Head of Biotech Private Investments at Wellington Management, Michelle Pernice, Operating Partner at Fairmount, Nimish Shah, Partner at Venrock Healthcare Capital Partners, and Dr. Violin.


Wedbush Securities Inc. is serving as exclusive strategic financial advisor and Gibson, Dunn & Crutcher LLP is serving as legal counsel to Korsana. Jefferies, TD Cowen, Stifel, UBS Investment Bank, and Wedbush & Co., LLC are serving as the placement agents to Korsana. Cooley LLP is serving as legal counsel to the placement agents. Gemini Valuation Services, LLC is serving as financial advisor and Ropes & Gray LLP is serving as legal counsel to Cyclerion.


Conference Call Details


The companies will hold a joint conference call on April 1, 2026, at 8:00 am ET to discuss the details of the proposed transactions.


Please access the presentation by clicking on the following link: https://register-conf.media-server.com/register/BIdbeaaec6359f483ab6e6685bd93e6312


About KRSA-028


KRSA-028 is an investigational, shuttled antibody targeting amyloid beta designed to advance the future of Alzheimer’s treatment. KRSA-028 utilizes a proven mechanism of action, selectively binding forms of amyloid beta that are enriched in amyloid plaques. KRSA-028 leverages Korsana’s Therapeutic Targeting (THETA™) technology, which incorporates clinically validated transferrin receptor (TfR1) and Fc engineering and is designed to improve brain delivery, safety, and convenience.


About Cyclerion Therapeutics


Cyclerion is a biopharmaceutical company focused on developing treatments for neuropsychiatric diseases. Cyclerion’s foundational product candidate, CYC-126, is an individualized therapy for treatment-resistant depression, a condition with significant unmet medical need and substantial commercial opportunity.


For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on X (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).


About Korsana Biosciences


Korsana Biosciences was founded to reduce the burden of neurodegenerative diseases for patients and caregivers. Developed in partnership with Paragon Therapeutics, Therapeutic Targeting (THETA™) is a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Korsana is advancing a pipeline of innovative THETA-enabled therapies for neurodegenerative diseases, starting with KRSA-028 for the treatment of Alzheimer’s disease. For more information, please visit www.korsana.com.


Forward-Looking Statements


This press release contains forward-looking statements concerning Cyclerion, Korsana, the proposed pre-closing financing and the proposed merger (collectively, the “Proposed Transactions”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Cyclerion’s and Korsana’s management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Proposed Transactions and their expected effects, perceived benefits or opportunities, including expected investment amounts and proceeds from investors, and related timing with respect thereto; expectations regarding or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to KRSA-028, and any developments or results in connection therewith; the anticipated timing of the commencement of and results from those studies and trials; expectations regarding the use of proceeds, the sufficiency of post-transaction resources to support the advancement of Korsana’s pipeline through certain milestones and the time period over which the combined company’s post-transaction capital resources will be sufficient to fund the combined company’s anticipated operations; the combined company operating under the name Korsana Biosciences, Inc. and trading on Nasdaq under the ticker symbol “KRSA”; the expected ownership percentages of pre-merger Cyclerion and Korsana stockholders following the closing of the proposed merger; the potential for KRSA-028 to be a best-in-class treatment for Alzheimer’s disease; and the anticipated advancement of Korsana’s broader pipeline of THETA-enabled therapies for neurodegenerative diseases. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.


These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements, including, without limitation, the following: the risk that the Proposed Transactions may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the merger, including obtaining the requisite approvals of the stockholders of each of Cyclerion and Korsana and the effectiveness of the registration statement to be filed with the SEC in connection with the Proposed Transactions; risks related to the clinical development of KRSA-028, including the possibility of delays, unfavorable clinical results, safety or tolerability issues, or the failure to obtain regulatory approval; uncertainties regarding the capabilities and potential of the THETA platform and Korsana’s pipeline programs; the risk that the financing may not close or may not generate the anticipated proceeds; market, macroeconomic, or other conditions that could adversely affect the combined company’s cash runway or ability to raise additional capital; risks related to the integration of the two companies and the management of a newly public company; and the highly competitive nature of the Alzheimer’s disease and neurodegenerative disease therapeutic landscape, including the risk that competitors may develop superior or more cost-effective therapies.


Additional factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release are discussed in Cyclerion’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the SEC from time to time, and will be discussed in the registration statement to be filed by Cyclerion with the SEC in connection with the Proposed Transactions. Readers are cautioned not to place undue reliance on these forward-looking statements. Each of Cyclerion and Korsana expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. All forward-looking statements are made as of the date of this press release.


No Offer or Solicitation


This press release and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except in accordance with the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, no public offer will be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.


NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESS RELEASE IS TRUTHFUL OR COMPLETE.


Important Additional Information about the Proposed Transactions Will be Filed with the SEC


This press release is not a substitute for the registration statement or for any other document that Cyclerion may file with the SEC in connection with the Proposed Transactions. In connection with the Proposed Transactions between Cyclerion and Korsana, Cyclerion intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus of Cyclerion. CYCLERION URGES INVESTORS AND SHAREHOLDERS TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CYCLERION, KORSANA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Cyclerion with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Shareholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the Proposed Transactions. In addition, investors and shareholders should note that Cyclerion communicates with investors and the public using its website (www.cyclerion.com).


Participants in the Solicitation


Cyclerion, Korsana and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Proposed Transactions. Information about Cyclerion’s directors and executive officers, including a description of their interests in Cyclerion, is included in Cyclerion’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q filed with the SEC, including any information incorporated therein by reference, as filed with the SEC, and other documents that may be filed from time to time with the SEC. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement/prospectus relating to the Proposed Transactions when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401287952/en/
For Korsana Investor and Media Inquiries:

info@korsana.com


For Cyclerion Investor and Media Inquiries:

IR@cyclerion.com


Original: Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

$CYCN -Medsteer Strategic Collaboration: Cyclerion has entered into an option-to-license agreement with Medsteer SAS (“Medsteer”), a recognized leader in closed-loop anesthetic delivery solutions, providing access to validated EEG-guided closed-loop control technology, including computational control modules, control software, and extensive annotated datasets. Medsteer’s technology is supported by experienced engineering capabilities developed across more than 25 clinical settings and more than 9,000 patients.
@Cyclerion

@Nasdaq
https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-therapeutics-announces-strategic-agreement-medsteer/

Nice! Thank you!

CYCN.......................................https://stockcharts.com/sc3/ui/?s=CYCN&p=w&b=5&g=0&id=p86431144783

CYCN Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression https://investorshub.advfn.com/stock-market/NASDAQ/cyclerion-therapeutics-CYCN/stock-news/97553355/cyclerion-therapeutics-announces-strategic-agreeme

Your very welcome...🥳...you just have to search until you find what you need...it's there...

Thank you!

Thank you!

https://finance.yahoo.com/news/exclusive-cycurion-wins-1-million-141611684.html

$CYCn UP 67% a/h can't find news

CYCN.......................................................................................a/h

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement –

– Webcast to be held September 24, 2025 at 10:30 a.m. ET –

CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology (“MIT”), securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement marks a pivotal milestone in Cyclerion’s transformation into a new, innovation-driven company focused on delivering potential novel, improved or first--in-class therapies for neuropsychiatric conditions with large unmet needs, beginning with treatment-resistant depression (“TRD”).

“This relaunch represents a pivotal moment for Cyclerion Therapeutics as we refocus our efforts on advancing breakthrough neuropsychiatric treatments for patients who have limited therapeutic options today,” said Dr. Errol DeSouza, a leader in the advancement of treatments for Central Nervous Disorders and Chairperson of Cyclerion’s Board of Directors. “Our board remains committed to partnering with management to support the strategic vision and ensure we have the resources necessary to develop innovative therapies that can meaningfully improve outcomes for individuals suffering from serious neuropsychiatric conditions. We believe this new chapter positions the company to make a significant impact in this underserved therapeutic area while creating sustainable value for all stakeholders.”

Cyclerion’s lead program leverages common anesthetic agents and a proprietary, tech-driven system to resynchronize communication between key brain regions and restore functional connectivity in patients with TRD. For the 3 million Americans living with TRD, this approach could deliver a long-awaited alternative to current limited treatment options.

“Cyclerion’s approach to drug development is grounded in compelling science and clinical precedent,” said Steven Hyman, M.D., Director of the Program in Brain Health at the Broad Institute and member of Cyclerion’s Board of Directors. “By leveraging known anesthetic mechanisms and pairing them with intelligent delivery systems, Cyclerion is pioneering a new class of neuropsychiatric therapies that could offer meaningful relief to patients with treatment-resistant depression.”

Cyclerion’s relaunch is supported by a world-class team of experts in neuropsychiatry, anesthesiology, machine learning and therapeutic delivery. The Company’s operating model is designed to maximize value creation and advance programs through de-risked inflection points. A Phase 2 proof-of-concept trial for its lead program is expected to initiate in 2026, with an initial data set anticipated in 2027.

In addition to its lead program, Cyclerion is actively exploring expansion into other neuropsychiatric diseases. The company’s strategic vision includes building a pipeline of novel, improved or first-in-class therapies that combine clinical efficacy with commercial differentiation.

“This agreement marks the launch of a new era at Cyclerion,” said Regina Graul, Ph.D., Chief Executive Officer of Cyclerion. “We are building a company that combines the rigor of a leading biopharma with the agility of a startup. For patients who have exhausted traditional options and for those underserved by current treatments, our foundational therapeutic candidate could represent the future of care in treatment-resistant depression. We believe Cyclerion will lead the way in advancing precision neuropsychiatric solutions beyond TRD—potentially bringing forward additional therapies that are safe, effective and accessible.”

Webcast Information

Cyclerion will make a recorded webcast presentation available on its website tomorrow, September 24, 2025 at 10:30am Eastern Time, to discuss this milestone and the Company’s future plans. To access the webcast, please visit the “Events” page of the Cyclerion website at www.cyclerion.com. The replay will be available after posting and will remain archived for one year.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on X (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) is a clinical-stage biopharmaceutical company focused on building a new pipeline of therapeutics for neuropsychiatric diseases, with an individualized therapy for treatment-resistant depression (“TRD”) as its foundational product candidate. Given the significant unmet medical need in TRD,

$4.41 Relaunch as a psycho and depression company 

CYCN under $4

CYCN 10 Q due MONDAY 3/3

CYCN................................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

CYCN...$6.05...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31425

Monday, February 03, 2025 2:09:38 PM

Post#
31429
of 31433
CYCN...$5.68...HOD...🥳...off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 673136

Monday, February 03, 2025 1:54:57 PM

Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

CYCN...$5.68...HOD...🥳...off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 673136

Monday, February 03, 2025 1:54:57 PM

Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

CYCN......................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

One more round $4.56 + 16% 2m floater take profits  otw up $4.70s

CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

Ring the register $4.07$$$$

CYCN.......................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

cycn.........................................................a/h

CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

That's usually exactly what I do sometimes I'll gamble though and stay in longer like I did today :) good strategy 👍🏼

I just sell the top of the rips buy the dips so long as the trend stays bullish if it goes para after i sell thats ok too

Right on cue lol 

IM still holding from that past.. I'm feeling a pop 29 or 10 in the next hour

Automated wash trading, brazen manipulation of the PPS. The O/S is 2.7M shares, which means that each and every share issued and outstanding has changed hands, on average, over 40 times today. Once they turn their computers off, folks will be trapped with grossly overpriced bags.

I was out at 8.20 on that push for a quick 30%

Gave you green light alert at $4s premarket ..lol on the monthly chart all green with 3 hits the 3rd being today 

mhmm

Got a sale set at 9.70

6.45 here :)

Re loaded at 6.30 halted up back at HOD 8.40

Halted again $8.39

Ec

In at $4.30 out at $7.90 in 15 mins lol 

CYCN Boom